There is a growing body of evidence that demonstrates a correlation between circulating Z-AAT polymers and overall liver disease in AATD patients, thus, reducing serum Z-AAT is promising for overall patient outcomes49,50. This evidence concerns the gene SERPINA1 and alpha 1-antitrypsin deficiency.